Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Weight-loss jabs such as Mounjaro could also help minimise asthma symptoms in obese people, says a new study, as the NHS ...